疾病持续时间作为评估利拉鲁肽治疗 2 型糖尿病患者疗效的指标。
Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.
机构信息
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Internal Medicine, Slingeland Hospital, Doetinchem, the Netherlands.
出版信息
J Diabetes Investig. 2018 Jul;9(4):979-980. doi: 10.1111/jdi.12857.
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).
评论 Usui 等人的文章。一项对 69 例 2 型糖尿病肥胖患者的回顾性队列研究表明，利拉鲁肽作为胰岛素的附加疗法降低血糖的效果依赖于 2 型糖尿病患者β细胞的剩余功能。疾病持续时间越短，用利拉鲁肽瞬时替代胰岛素的反应预后越好（HR 2.39（95%CI：1.20-4.76））。
Zotero 插件